Ranking Alexa Global: # 8,101,472
Server:nginx/1.10.3 (Ubuntu...
The main IP address: 88.99.171.3,Your server United Kingdom,Rochdale ISP:Zen Internet Ltd TLD:bio CountryCode:GB
The description :news team we’re reinventing the way treatments for diseases with unmet medical need are discovered. is a biotech startup formed by mayo clinic and nference. scroll to discover scroll to discover why f...
This report updates in 27-Nov-2018
Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host qrativ.bio. Currently, hosted in United Kingdom and its service provider is Zen Internet Ltd .
Latitude: | 53.617660522461 |
Longitude: | -2.1552000045776 |
Country: | United Kingdom (GB) |
City: | Rochdale |
Region: | England |
ISP: | Zen Internet Ltd |
HTTP Header information is a part of HTTP protocol that a user's browser sends to called nginx/1.10.3 (Ubuntu) containing the details of what the browser wants and will accept back from the web server.
Content-Encoding: | gzip |
Transfer-Encoding: | chunked |
Server: | nginx/1.10.3 (Ubuntu) |
Connection: | keep-alive |
Link: | |
Date: | Tue, 27 Nov 2018 14:49:53 GMT |
Content-Type: | text/html; charset=UTF-8 |
soa: | ns15.domaincontrol.com. dns.jomax.net. 2018060805 28800 7200 604800 600 |
txt: | "v=spf1 a mx ptr include:secureserver.net ~all" "google-site-verification=BM6EVzho_VGCYTQ6j32Vhm5jEqxuieCadop2fpoTcso" |
ns: | ns16.domaincontrol.com. ns15.domaincontrol.com. |
ipv4: | IP:88.99.171.3 ASN:24940 OWNER:HETZNER-AS, DE Country:DE |
mx: | MX preference = 5, mail exchanger = alt2.aspmx.l.google.com. MX preference = 10, mail exchanger = alt3.aspmx.l.google.com. MX preference = 10, mail exchanger = alt4.aspmx.l.google.com. MX preference = 1, mail exchanger = aspmx.l.google.com. MX preference = 5, mail exchanger = alt1.aspmx.l.google.com. |
news team we’re reinventing the way treatments for diseases with unmet medical need are discovered. is a biotech startup formed by mayo clinic and nference. scroll to discover scroll to discover why focus on diseases with unmet medical need? there have been tremendous advances in understanding the biology of disease, but this explosion of knowledge has far outpaced the human ability to consume and make sense of it. this has created a challenge for scientists working to translate biomedical data into new treatments. this challenge is particularly significant for diseases with unmet medical need, such as rare diseases and diseases with highly targeted patient populations. for instance, only 1 in 20 rare diseases have a treatment. and while precision medicine - involving patient stratification informed by genomics – has started to revolutionize oncology, personalized medicine is still a nascent field beyond oncology. ~7,000 rare diseases ⟵ only ~350 treatments say goodbye to ‘re’ in drug repurposing. “we believe in the power of combining nference’s artificial intelligence (ai)-driven knowledge synthesis platform with mayo clinic’s medical expertise and clinical data, to discover and develop treatments for diseases with unmet medical need rapidly and efficiently.” – dr. andrew badley founder and chief medical officer @ the drug purposing platform the explosion in knowledge – driven by multidisciplinary omics data and biomedical literature - that is leveraged by nference’s knowledge synthesis platform, when partnered with expertise of mayo clinic physicians and scientists uniquely enables to purpose drugs in a data driven and systematic manner. knowledge synthesis with ai pubmed, clinical trials, sec... statistical inference mechanistic datasets (omics...) real world evidence (rwe) mayo clinic experts mayo clinic proprietary data de-identified electronic health records prescription and diagnosis data patient-treatment omics competitive landscape why drug purposing? 1 there are thousands of drugs in development, but most of them are not being tested to treat diseases with unmet medical need. out of the known 10,000 diseases, 7,000 of them are rare diseases. however, only 600 of 6,000 drugs in development are being evaluated for rare diseases. 2 drugs have been successfully repurposed in the past, but this has typically happened late in their development and not in a systematic manner. thalidomide, a drug originally tested for morning sickness in pregnant women in the 1960’s, wasn’t approved by the fda until the 2000’s when it was approved to treat multiple myeloma. 3 systematic drug purposing – starting early in drug development – can lead to identification of treatments more rapidly and efficiently. the search for all possible uses of a drug needs to start during the early stages of development – that’s why we call this approach drug purposing… and not repurposing. 4 and systematic drug purposing is now a possibility… with our platform – darwin.ai. darwin.ai – built with proprietary data from mayo clinic and nference’s knowledge synthesis platform – makes us uniquely suited to enable systematic drug purposing. let’s make a difference for patients, together. biotechnology and pharmaceutical companies leverage our drug purposing platform, darwin.ai, to identify all possible uses for their drugs since their early phases of development. through these relationships, we can maximize every drug’s potential for as many patients and diseases as possible. our approach is beneficial to everyone involved. it has the potential of benefiting patients who desperately need new treatments, and it also benefits companies by allowing them to maximize the value of their internal drug pipelines. how it works. step 1. discover new purposes for your drugs: find subsets of patients who would respond favorably to your drugs. -or- find diseases with high unmet medical need that could be effectively treated with your drugs. step 2. making it happen: if the identified opportunity falls within your areas of focus, we can help you pursue this opportunity in a variety of ways… such as by planning and conducting trials at mayo. -or- if the new opportunity falls outside your areas of focus, we can discuss about our in-licensing interest such that we can take the lead on pursuing that opportunity. contact us we are co-located in cambridge, ma (at kendall square – the world’s largest biotech hub) and rochester, mn (mayo clinic’s main campus). you may reach us at: [email protected] 101 main street 15th floor cambridge, ma 02142 visit nference mayo clinic business accelerator 221 1st ave sw rochester, mn 55902 visit mayo clinic copyright 2018 by | terms of use | privacy policy home mission solution partnerships contact
http://qrativ.bio/#solution
http://qrativ.bio/privacy_policy
http://qrativ.bio/team
http://qrativ.bio/#mission
http://qrativ.bio/#partnerships
http://qrativ.bio/#hero
http://qrativ.bio/news
http://qrativ.bio/#contact
http://qrativ.bio/terms
Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;
Go to top
The following list shows you to spelling mistakes possible of the internet users for the website searched .